Senolytic treatment for low back pain.

Area of Science:

• Gerontology
• Cellular Biology
• Pain Research

Background:

• Senescent cells (SnCs) accumulate with age and stress, releasing inflammatory factors (SASP).
• SASP contributes to age-related diseases, including low back pain (LBP).
• Senolytics o-vanillin and RG-7112 clear SnCs and reduce SASP in human intervertebral discs (IVDs).

Purpose of the Study:

• To investigate the efficacy of o-vanillin and RG-7112 in treating LBP.
• To determine if these senolytics can reduce pain and degeneration associated with LBP in a mouse model.

Main Methods:

• SPARC mice with LBP were orally administered o-vanillin and RG-7112 (single or combination).
• Evaluated LBP, SASP factor release, SnC burden in IVD and spinal cord.
• Assessed IVD degeneration, vertebral bone quality, and spinal cord pain marker expression.

Main Results:

• Treatment with o-vanillin and RG-7112 significantly reduced LBP and SASP factor release.
• SnCs were cleared from the IVD and spinal cord following treatment.
• IVD degeneration scores decreased, vertebral bone quality improved, and spinal pain markers were reduced.

Conclusions:

• O-vanillin and RG-7112 demonstrate therapeutic potential for LBP by targeting senescent cells.
• These senolytics may serve as disease-modifying agents for LBP and other painful senescence-associated disorders.